First ‘NOAC’ antidote, Praxbind, counting down for domestic introduction
The first NOAC antidote is expected to be introduced in Korea.
According to the industry concerned on the 17th, Boehringer Ingelheim recently turned in the approval application of ‘Praxbind(idaruxizumab),’ an antibody of the oral anti-coagulant(NOAC) ‘Pradaxa(dabigatran),’ to the Ministry of Foo...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
